Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy
Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled…
13/05/2022 - 4 minutes
Cancer: Keep up to Date with the Latest in Oncology
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
Show More
Editor's Picks for Cancer
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Immuno-Oncology: From Science Fiction to the Mainstream
- ADC Approval Buoys Spirits in Cancer Treatment Space
- Do Natural Killer Cells Hold the Key to Treating Blood Cancers?
- Meet 20 European Immuno-Oncology Companies that are Fighting Cancer
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest Cancer Articles
Exosome Therapy: Borrowing from Nature’s Toolbox
In just a few years, exosomes have started gaining recognition as a solution to deliver…
09/05/2022 - 11 minutes
Amphista Lands Megadeals to Smash Cancer using Protein Degradation
As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation…
05/05/2022 - 3 minutes
Tubulis Rides Investment Wave in ADCs with €60M Series B
The German firm Tubulis has raised a €60M Series B round to advance cancer drugs…
03/05/2022 - 3 minutes
Cancer Research UK Deploys €700M to Foster Oncology Startups
In a show of strength after an income squeeze during the Covid-19 pandemic, the charity…
27/04/2022 - 4 minutes
Immunocore Approvals Open Door for TCR Cancer Drugs
The EU has followed the FDA in granting market approval to Kimmtrak, the first-ever bispecific…
06/04/2022 - 3 minutes
Precision Medicine Startups Increase Focus on Data Access and Privacy
Low-cost genetic sequencing is becoming increasingly accessible and profitable for companies, but data protection and…
31/03/2022 - 4 minutes
€80M Series B Establishes European Champion in Radiopharmaceuticals
Big European venture capital firms Jeito, Forbion, and Inkef Capital have teamed up to propel…
17/03/2022 - 4 minutes
Sponsored
by Takara Bio
Combination Therapies: Opportunities for Improved CAR-T Cell Therapy?
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
10/03/2022 - 6 minutes
Sponsored
by Precision for Medicine
Using the Full Potential of Circulating Tumor Cells for Oncology Clinical Trials
Circulating tumor cell counts are powerful prognostic factors for cancer patients. Recent research has found…
09/02/2022 - 5 minutes
Norwegian Biotech Put on the Map with €18M Oncology Round
The immuno-oncology startup Cytovation has raised €17.7M (NOK 180M) in one of Norway's biggest Series…
26/01/2022 - 3 minutes
Sponsored
by Indivumed
How is Spatial Transcriptomics Changing the Immuno-Oncology Field?
The advent of next-generation sequencing has led to the rise of novel gene expression profiling…
23/11/2021 - 7 minutes
